MOTS-C
MOTS-C Original price was: $50.00.Current price is: $35.00.
Back to products
Ipamorelin
Ipamorelin Original price was: $70.00.Current price is: $49.00.

Melanotan-2 (MT-II)

Original price was: $45.00.Current price is: $31.50.

Melanotan-2 (MT-II) is a synthetic cyclic heptapeptide analogue of α-MSH and a non-selective melanocortin receptor agonist (primarily MC1R, MC3R, MC4R and MC5R; minimal activity at MC2R). It is supplied as a high-purity lyophilized powder and used in research on melanogenesis/photobiology and central melanocortin pathways.

Description

Product details

Amino Acid Sequence

Ac-Nle-cycloAsp−His−D−Phe−Arg−Trp−LysAsp-His-D-Phe-Arg-Trp-LysAsp−His−D−Phe−Arg−Trp−Lys-NH₂ (lactam bridge Asp²–Lys⁷)

Molecular Formula

C₅₀H₆₉N₁₅O₉

Molecular Weight

1024.2 g/mol

PubChem CID

92432

CAS Number

121062-08-6

Vial Size

3ml

Contents

Lyophilized powder, white/off-white color

Mechanism of action

Melanocortin receptor agonism (MC1R/3R/4R/5R)

MT-II activates melanocortin GPCRs; MC1R drives melanogenesis in skin, while MC3R/MC4R mediate central effects (e.g., sexual function, energy balance).

Melanogenesis & photobiology

MC1R stimulation increases eumelanin via cAMP/MITF/tyrosinase pathways; increased melanin is broadly photoprotective. (Context from α-MSH/melanocortin literature.)

Central neurosexual effects (MC4R-linked)

Studies with MT-II demonstrate erectogenic and pro-desire effects, consistent with central melanocortin pathway activation.

Storage & handling

Storage:

Store the lyophilized vial in a cool, dry area protected from direct sunlight.
Legal Disclaimer

All products on this site are for research and development, laboratory, or analytical use only; they are not for human consumption, medical, diagnostic, cosmetic, veterinary, or any other non-research application. The statements and products have not been evaluated by the U.S. Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. Honest Peptide is not a compounding pharmacy or chemical compounding facility as defined under section 503A of the Federal Food, Drug, and Cosmetic Act, nor an outsourcing facility as defined under section 503B.